Low Dose Versus Usual Dose Dexamethasone for Symptom Control in Children Undergoing Cranial or Craniospinal Radiation

Headache Clinical Trial

Official title:

A RANDOMIZED CONTROLLED MULTICENTER NON-INFERIORITY TRIAL OF TWICE DAILY LOW DOSE DEXAMETHASONE VERSUS USUAL DOSE DEXAMETHASONE FOR SYMPTOM CONTROL IN CHILDREN WITH A BRAIN TUMOUR UNDERGOING CRANIAL OR CRANIOSPINAL RADIATION

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01135550
• Other study ID #: 1000014713
• Status: Terminated
• Phase: Phase 3
• First received: June 1, 2010
• Last updated: May 3, 2016
• Start date: June 2010
• Est. completion date: December 2013

Study information

• Verified date: May 2016
• Source: The Hospital for Sick Children
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of low dose dexamethasone versus high dose dexamethasone in the treatment of radiation induced vomiting.

Description:

Dexamethasone is an effective medication to ameliorate radiation induced headache and vomiting. In our Toronto experience dexamethasone in low doses (1 mg/m2/day) is sufficient in treating these symptoms. However this experience is not shared from many neuro-oncology centers of excellence that more commonly use 5 mg/m2/day according to the results of the trans-Canadian survey. A prospective multicenter trial evaluating the effectiveness of dexamethasone in different dose regimens in symptomatic children while undergoing CNS radiation will elucidate the appropriate dose.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 25
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years to 18 Years

Eligibility

Inclusion Criteria for Enrolment:

• Children between 2-18 years of age.

• Children who underwent resection of a brain tumour with = 1.5 cm2 residual tumour after surgical resection.

• Children regardless of extent of leptomeningeal or spinal metastasis (M1-3) are eligible.

• Children who undergo focal or whole brain (± spinal) radiation as part of their brain tumour treatment.

• Children treated at one of the 16 tertiary care centers in Canada (CPBTC).

• Patients on any anticonvulsive treatment are eligible.

• Patients on concomitant chemotherapy while undergoing radiation are eligible.

• Patients must be = 24 hours steroid-free prior to starting radiation.

• Parents/legal guardians have to have signed and dated an informed consent to allow study enrolment of their child. (As per institutional guidelines, patients over a certain age may have signed their own informed consent form.)

• Patients > 8 years of age should assent to study participation.

• Patients less than 10 years of age should have a Lansky Score of >/= 50.

• Patients 10 years of age or older should have a Karnofsky Score of >/= 50. If ECOG performance scale is used, patient should have a score of 0, 1 or 2.

Exclusion Criteria for Enrolment:

• Children with residual brain tumour lesion > 1.5 cm2 after surgical resection.

• Children on steroids (dexamethasone) that will not be stopped = 24 hours prior to start of radiation therapy.

Inclusion Criteria for Randomization to a Dexamethasone treatment group:

• Patients must have been enrolled on the Dexamethasone study prior to the start of radiation therapy.

• Children who develop either symptoms of vomiting (defined as either retching or vomiting = once per day) or headache (= 2 points increase in severity of the most intense headache/day) while undergoing irradiation.

• Patients who are currently undergoing focal or whole brain (± spinal) radiation.

Exclusion Criteria for Randomization to a Dexamethasone treatment group:

• Patients who were not enrolled on Dexamethasone study prior to start of radiation therapy.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Headache
• Vomiting

Intervention

Drug:
• High dose dexamethasone
Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form. If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4.
• Low dose dexamethasone
Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form. If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4.

Locations

Country	Name	City	State
Canada	Alberta Children's Hospital	Calgary	Alberta
Canada	McMaster University Hospital	Hamilton	Ontario
Canada	Children's Hospital of Western Ontario	London	Ontario
Canada	The Hospital for Sick Children	Toronto	Ontario
Canada	BC Children's Hospital	Vancouver	British Columbia

Sponsors (2)

Lead Sponsor	Collaborator
The Hospital for Sick Children	C17 Council

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of dexamethasone on vomiting	The primary outcome will be the evaluation of effectiveness of dexamethasone on vomiting after 24-48 hours (after 2-4 doses of treatment). Vomiting is defined as either retching or vomiting and will be counted in events. The frequency of emetic episodes/day will be documented in the daily diary. The effectiveness of dexamethasone will be counted in number of episodes and evaluated on day 2 (48 hours after first dose).	24-48 hours after first dose of dexamethasone	No
Secondary	Headaches	Parent/patients are asked to document the worst headache of the day prior to bedtime daily on a visual analogue scale using the 6-face "happy face" scale ranging from 0 (no headache) to 5 (extreme headache).	0-48 hours after first dose of dexamethasone	No
Secondary	Adverse events and side effects	These will be described with numbers, type and frequencies for the duration of the subjects participation in the study.	Duration of participation in study	Yes
Secondary	Quality of life	Parent/patient will complete a quality of life assessment within 14 days prior to starting radiation (including first day of radiation) and within 14 days post completion of radiation (including last day of radiation).	Baseline and at end of participation in study	No